Assessing The Effect of Apixaban on Endogenous Fibrinolysis in Patients With Non-Valvular Atrial Fibrillation
Phase of Trial: Phase IV
Latest Information Update: 14 Feb 2019
Price : $35 *
At a glance
- Drugs Apixaban (Primary) ; Aspirin; Warfarin
- Indications Stroke; Thromboembolism
- Focus Therapeutic Use
- 06 Feb 2019 Status changed from recruiting to completed.
- 31 Aug 2018 Biomarkers information updated
- 25 Oct 2017 Status changed from not yet recruiting to recruiting.